報價延遲最少15分鐘:2026/04/25 20:48 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3878 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-22.97/-0.04
|
|
企業價值
21.11M
|
| 資產負債 |
|
每股賬面淨值
-1.52
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.39M
|
|
每股收益
0.85
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Companyfocuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. |
